AXA Framlington Biotech Fund - R Income

Category Sector Equity Biotechnology


star-filledstar-filledstar-filledstar-filled
Last buy/sell price

262.50p

arrow-down-2.80p (-1.06%)

Fund Code

3100725

GB0031007254

Prices updated as at 07 Jan 2025
|
Prices in GBX

Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.

Portfolio as of 30/11/2024

Asset allocation

Show long & short position

Geographical breakdown

Continent or country allocation (%)

Market classification (%)

Stock style

Large value

17.82%

% Weight
Value
Core
Growth
Large

18

17

5

Medium

1

17

13

Small

4

10

16

Valuation

AXA Framlington Biotech Fund - R Income
Sector Equity Biotechnology

17.97

17.97
21.76

6.30

6.30
6.93

3.78

3.78
3.72

13.85

13.85
13.84

Growth rate

AXA Framlington Biotech Fund - R Income
Sector Equity Biotechnology

11.54%

11.54%
20.58%

0.56%

0.56%
0.36%

-9.27%

-9.27%
-7.54%

Top 10 holdings

1
Vertex Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
8.20317
2
Regeneron Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
6.48047
3
Amgen Inc
Sector
-
Country
United States
% of assets
6.04558
4
AstraZeneca PLC ADR
Sector
-
Country
United Kingdom
% of assets
5.43078
5
argenx SE ADR
Sector
-
Country
United States
% of assets
3.87252
6
Alnylam Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
3.78835
7
Gilead Sciences Inc
Sector
-
Country
United States
% of assets
3.71213
8
Insmed Inc
Sector
-
Country
United States
% of assets
3.23498
9
United Therapeutics Corp
Sector
-
Country
United States
% of assets
3.07709
10
Novo Nordisk AS Class B
Sector
-
Country
Denmark
% of assets
2.79682
Assets in top 10 holdings %

46.64%

Total no. of equity holdings

52.00

Total no. of bond holdings

-

Stock sectors

AXA Framlington Biotech Fund - R Income
Sector Equity Biotechnology

0.00%

Basic materials

-
-

Con cyclical

-
-

Financial svs

-
-

Real estate

-
-

0.00%

Comm services

-
-

Energy

-
-

Industrials

-
-

Technology

-
-

100.00%

Con defensive

-
-

Healthcare

100.00%
-

Utilities

-
-


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.


Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
© Copyright 2024 Morningstar. All rights reserved.